PMC:7172841 / 1847-2256 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T20","span":{"begin":32,"end":42},"obj":"Body_part"},{"id":"T21","span":{"begin":119,"end":132},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma63261"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma264829"}],"text":"ted with COVID-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\nIn December 2019, authorities in Wuhan, China reported a cluster of pneumonia cases caused by an unknown etiologic agent. The pathogen was soon identified and sequenced as a novel "}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T26","span":{"begin":9,"end":17},"obj":"Disease"},{"id":"T27","span":{"begin":32,"end":62},"obj":"Disease"},{"id":"T28","span":{"begin":297,"end":306},"obj":"Disease"}],"attributes":[{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"ted with COVID-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\nIn December 2019, authorities in Wuhan, China reported a cluster of pneumonia cases caused by an unknown etiologic agent. The pathogen was soon identified and sequenced as a novel "}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T18","span":{"begin":43,"end":53},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T19","span":{"begin":119,"end":132},"obj":"http://purl.obolibrary.org/obo/PR_000001393"},{"id":"T20","span":{"begin":284,"end":285},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T21","span":{"begin":401,"end":402},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"ted with COVID-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\nIn December 2019, authorities in Wuhan, China reported a cluster of pneumonia cases caused by an unknown etiologic agent. The pathogen was soon identified and sequenced as a novel "}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T15","span":{"begin":88,"end":95},"obj":"Chemical"},{"id":"T16","span":{"begin":137,"end":139},"obj":"Chemical"}],"attributes":[{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A17","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"ted with COVID-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\nIn December 2019, authorities in Wuhan, China reported a cluster of pneumonia cases caused by an unknown etiologic agent. The pathogen was soon identified and sequenced as a novel "}

    LitCovid-PD-GO-BP

    {"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T13","span":{"begin":32,"end":53},"obj":"http://purl.obolibrary.org/obo/GO_0042116"},{"id":"T14","span":{"begin":88,"end":108},"obj":"http://purl.obolibrary.org/obo/GO_0019882"}],"text":"ted with COVID-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\nIn December 2019, authorities in Wuhan, China reported a cluster of pneumonia cases caused by an unknown etiologic agent. The pathogen was soon identified and sequenced as a novel "}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T19","span":{"begin":134,"end":214},"obj":"Sentence"},{"id":"T20","span":{"begin":216,"end":228},"obj":"Sentence"},{"id":"T21","span":{"begin":229,"end":350},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ted with COVID-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\nIn December 2019, authorities in Wuhan, China reported a cluster of pneumonia cases caused by an unknown etiologic agent. The pathogen was soon identified and sequenced as a novel "}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T12","span":{"begin":168,"end":188},"obj":"Phenotype"},{"id":"T13","span":{"begin":297,"end":306},"obj":"Phenotype"}],"attributes":[{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002958"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"ted with COVID-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\nIn December 2019, authorities in Wuhan, China reported a cluster of pneumonia cases caused by an unknown etiologic agent. The pathogen was soon identified and sequenced as a novel "}

    LitCovid-PMC-OGER-BB

    {"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T75","span":{"begin":9,"end":17},"obj":"SP_7"},{"id":"T76","span":{"begin":32,"end":42},"obj":"CL:0000235;GO:0042116"},{"id":"T77","span":{"begin":43,"end":53},"obj":"GO:0042116"},{"id":"T78","span":{"begin":88,"end":95},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T79","span":{"begin":119,"end":132},"obj":"PR:000001393"},{"id":"T80","span":{"begin":137,"end":141},"obj":"PR:000001393"},{"id":"T81","span":{"begin":168,"end":174},"obj":"UBERON:0002405;GO:0006955"},{"id":"T82","span":{"begin":175,"end":188},"obj":"GO:0006955"}],"text":"ted with COVID-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\nIn December 2019, authorities in Wuhan, China reported a cluster of pneumonia cases caused by an unknown etiologic agent. The pathogen was soon identified and sequenced as a novel "}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"95","span":{"begin":119,"end":132},"obj":"Gene"},{"id":"96","span":{"begin":137,"end":141},"obj":"Gene"},{"id":"97","span":{"begin":205,"end":213},"obj":"Species"},{"id":"100","span":{"begin":9,"end":17},"obj":"Disease"},{"id":"101","span":{"begin":32,"end":62},"obj":"Disease"},{"id":"126","span":{"begin":297,"end":306},"obj":"Disease"}],"attributes":[{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"Gene:3569"},{"id":"A96","pred":"tao:has_database_id","subj":"96","obj":"Gene:3569"},{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"Tax:9606"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"MESH:C000657245"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"MESH:D055501"},{"id":"A126","pred":"tao:has_database_id","subj":"126","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ted with COVID-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\nIn December 2019, authorities in Wuhan, China reported a cluster of pneumonia cases caused by an unknown etiologic agent. The pathogen was soon identified and sequenced as a novel "}